You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
復星醫藥(02196.HK)擬2.18億新幣收購新加坡私立腫瘤專科醫療中心

格隆匯6月6日丨復星醫藥(02196.HK)宣佈,於2022年6月6日,買方(公司附屬公司)透過(i)Solid Success股權轉讓協議,及(ii)其他股東股權轉讓協議,由買方擬以分別不超過1.85021億新幣及3265.1萬新幣的現金對價向賣方一及賣方二分別收購目標公司ONCOCARE MEDICAL PTE. LTD.51%及9%股權。建議收購完成後,目標公司將成為公司附屬公司。

據悉,目標公司為一間於新加坡註冊成立的有限責任公司,是目前新加坡最大的私立腫瘤專科醫療中心之一,,匯聚新加坡數名多學科腫瘤診療專家及姑息治療專家,為新加坡本地及國際患者提供一站式多學科的腫瘤篩查、診斷、藥物治療、臨終關懷等專業醫療服務,以乳腺癌、肺癌、腸癌治療見長,並以腫瘤免疫治療和腫瘤靶向治療為其特色及優勢領域。目標公司在新加坡主要私立醫療中心共設有7間診所,其中包括了新加坡唯一的私立婦女腫瘤醫療中心。於公吿日期,賣方一持有目標公司51%的股權,其實際控制人為劉殿波先生。

公吿稱,目標公司目前是新加坡最大的私立腫瘤專科醫療中心之一。目標公司依託於當地健全的醫療體系、快速的藥物上市審評機制、完善的保險支付系統和廣泛的藥物可及,以腫瘤免疫治療和腫瘤靶向治療為其特色及優勢領域。建議收購完成後,將拓展集團醫療健康服務業務在東南亞地區的佈局,並有利於推動集團在腫瘤治療領域全方位解決能力的提升。 

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account